XML 75 R52.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaborative Arrangements - Schedule of Collaborative Arrangement Transactions (Details) - Collaborative Arrangement - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
AstraZeneca      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Receivables from counterparty $ 12    
Payables to counterparty 643    
AstraZeneca | Total Sales      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Total Sales 20    
AstraZeneca | Materials and production costs      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Expenses 4    
AstraZeneca | Marketing and administrative expenses      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Expenses 1    
AstraZeneca | Research and development expenses      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Expenses 2,419    
Bayer AG      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Receivables from counterparty 33 $ 0  
Payables to counterparty 352 353  
Bayer AG | Total Sales      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Product sales, net 149 88 $ 0
Profit sharing 151 81 30
Total Sales 300 169 30
Bayer AG | Materials and production costs      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Expenses 99 133 67
Bayer AG | Marketing and administrative expenses      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Expenses 27 26 3
Bayer AG | Research and development expenses      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Expenses $ 96 $ 45 $ 3